PIK3CA and neoplasm: While recently incorporated PI3K and AKT inhibitor-based therapies rely on droplet digital PCR (ddPCR) tests or next-generation sequencing (NGS) screening for PIK3CA and AKT hotspot mutations or PTEN loss, these FDA-approved tests are precise and convenient as they can utilize tumor tissue and/or circulating tumor DNA.